Acepodia, a pioneer in cell therapy development, has partnered with Pfizer through its Pfizer Ignite initiative to expand the potential of its innovative Antibody-Cell Conjugation (ACC) platform into the realm of autoimmune diseases. This strategic alliance will harness Pfizer’s extensive resources and expertise to further Acepodia’s clinical trials, notably ACE1831 for non-Hodgkin’s lymphoma and ACE2016 for solid tumors.
The ACC technology, founded on the groundbreaking work of Nobel laureate Dr. Carolyn Bertozzi, offers a non-genetically modified alternative to CAR-T therapies. This method notably mitigates the severe side effects like cytokine release syndrome, associated with traditional CAR-T treatments. Currently, ACE1831 is undergoing phase 1 trials and showing promising results in enhancing patient outcomes with minimal adverse effects.
This collaboration underscores Acepodia’s commitment to addressing critical needs in autoimmune treatments, leveraging Pfizer Ignite’s capability to refine drug development processes. Acepodia maintains autonomy over the development and potential licensing of its innovations, promising to deliver transformative treatments to patients with unmet medical needs.
About Acepodia: Acepodia is a clinical-stage biotech leader focused on revolutionizing cancer treatment with its proprietary ACC platform, linking tumor-targeting antibodies to powerful immune cells. The company aims to expand its pipeline to include a wider range of cancers and autoimmune diseases, offering new hope through more accessible and effective cellular therapies.
